Nordea Investment Management AB Buys 1,210 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Nordea Investment Management AB increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.3% during the 2nd quarter, Holdings Channel.com reports. The firm owned 17,839 shares of the medical equipment provider’s stock after acquiring an additional 1,210 shares during the quarter. Nordea Investment Management AB’s holdings in Zimmer Biomet were worth $1,628,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of ZBH. New York State Teachers Retirement System boosted its position in Zimmer Biomet by 0.5% in the 2nd quarter. New York State Teachers Retirement System now owns 157,785 shares of the medical equipment provider’s stock valued at $14,392,000 after buying an additional 851 shares during the last quarter. Generali Asset Management SPA SGR boosted its holdings in Zimmer Biomet by 16.9% in the second quarter. Generali Asset Management SPA SGR now owns 14,110 shares of the medical equipment provider’s stock valued at $1,287,000 after acquiring an additional 2,042 shares during the last quarter. Boston Trust Walden Corp increased its position in Zimmer Biomet by 45.0% in the second quarter. Boston Trust Walden Corp now owns 693,322 shares of the medical equipment provider’s stock worth $63,238,000 after purchasing an additional 215,249 shares during the period. Sequoia Financial Advisors LLC boosted its stake in shares of Zimmer Biomet by 492.4% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 87,885 shares of the medical equipment provider’s stock valued at $8,016,000 after purchasing an additional 73,049 shares during the last quarter. Finally, MGO One Seven LLC grew its position in shares of Zimmer Biomet by 59.7% during the 2nd quarter. MGO One Seven LLC now owns 3,717 shares of the medical equipment provider’s stock worth $339,000 after buying an additional 1,389 shares during the period. Institutional investors own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ZBH. UBS Group lifted their target price on shares of Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a report on Friday, August 8th. Royal Bank Of Canada set a $111.00 target price on Zimmer Biomet in a research report on Friday, October 10th. BTIG Research increased their price target on shares of Zimmer Biomet from $118.00 to $122.00 and gave the company a “buy” rating in a research report on Monday, October 13th. Raymond James Financial upped their target price on shares of Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. Finally, Stifel Nicolaus boosted their price target on shares of Zimmer Biomet from $115.00 to $118.00 and gave the company a “buy” rating in a report on Friday, September 19th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $111.94.

Zimmer Biomet Trading Up 1.2%

Shares of NYSE:ZBH opened at $103.87 on Thursday. The company’s 50-day moving average price is $101.83 and its two-hundred day moving average price is $97.72. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $114.72. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The stock has a market capitalization of $20.58 billion, a PE ratio of 25.27, a price-to-earnings-growth ratio of 2.36 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. During the same quarter in the previous year, the business earned $2.01 earnings per share. Zimmer Biomet’s quarterly revenue was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio is presently 23.36%.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.39% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.